Rafa Laboratories, Ltd.
Rafa is a leading pharmaceutical company in Israel, founded in 1937, specializing in the manufacturing, marketing, and distribution of prescription and over-the-counter medicines. The company is committed to providing high therapeutic value products and has a strong focus on partnerships and innovation in the healthcare sector.
Industries
Nr. of Employees
medium (51-250)
Rafa Laboratories, Ltd.
Shlomo Halevi 5, Jerusalem of Silver building, Har Hotzvim, P.O. 405, Jerusalem, 9777019
Products
Portfolio of prescription (Rx) and over-the-counter (OTC) medicines
A commercial portfolio that includes proprietary and generic prescription medicines and OTC consumer health products across multiple therapeutic areas.
Therapeutic-area product offerings
Marketed and manufactured products addressing pain, palliative care, gastrointestinal, respiratory, dermatology, psychiatry and selected consumer health indications (for example lice treatments).
Portfolio of prescription (Rx) and over-the-counter (OTC) medicines
A commercial portfolio that includes proprietary and generic prescription medicines and OTC consumer health products across multiple therapeutic areas.
Therapeutic-area product offerings
Marketed and manufactured products addressing pain, palliative care, gastrointestinal, respiratory, dermatology, psychiatry and selected consumer health indications (for example lice treatments).
Services
End-to-end manufacturing services from development to commercial production, including scale-up, bulk manufacturing and method transfer for third-party pharmaceuticals.
Production across solid, semi-solid and liquid lines with primary and secondary packaging capabilities and serialization.
Regulatory support for product registration and compliance with local and international authorities, including expertise in Israeli, EMA and FDA processes.
Market access strategy, pricing and reimbursement support to accelerate product reimbursement and patient access in the local market.
Local sales and marketing services including field teams and distribution to hospitals, clinics, HMOs and pharmacy chains; support for product launches and lifecycle management.
Pharmacovigilance operations and medical information services to support safety monitoring and regulatory compliance.
End-to-end manufacturing services from development to commercial production, including scale-up, bulk manufacturing and method transfer for third-party pharmaceuticals.
Production across solid, semi-solid and liquid lines with primary and secondary packaging capabilities and serialization.
Regulatory support for product registration and compliance with local and international authorities, including expertise in Israeli, EMA and FDA processes.
Market access strategy, pricing and reimbursement support to accelerate product reimbursement and patient access in the local market.
Local sales and marketing services including field teams and distribution to hospitals, clinics, HMOs and pharmacy chains; support for product launches and lifecycle management.
Pharmacovigilance operations and medical information services to support safety monitoring and regulatory compliance.
Expertise Areas
- Contract development and manufacturing (CDMO)
- Sterile and aseptic manufacturing
- Formulation development and combination-device formulations
- Commercial-scale manufacturing and scale-up
Key Technologies
- Aseptic/sterile manufacturing processes
- Pre-filled syringe and autoinjector-compatible formulation
- Multi-layer tablet production and coating
- Liquid suspension and solution formulation
News & Updates
Rafa recently secured a 45 million $US deal with the US Department of Defense for its midazolam autoinjector which was approved by the US-FDA in 2022.
Rafa Laboratories LTD. is pleased to announce the U.S. Food and Drug Administration has approved its 'first in market' 10 mg midazolam autoinjector for the treatment of status epilepticus in adults.
Rafa recently secured a 45 million $US deal with the US Department of Defense for its midazolam autoinjector which was approved by the US-FDA in 2022.
Rafa Laboratories LTD. is pleased to announce the U.S. Food and Drug Administration has approved its 'first in market' 10 mg midazolam autoinjector for the treatment of status epilepticus in adults.